PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3.38%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.01%. Joel Greenblatt would investigate if growth quality matches quantity.
-90.81%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive advantage potential.
44.31%
Growth of 44.31% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
48.17%
Margin change of 48.17% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
-50.01%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-27.45%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
-20.71%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
31.32%
Other expenses change of 31.32% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
-24.61%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 6.34%. Seth Klarman would investigate advantages.
-46.09%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is 5.79%. Seth Klarman would investigate advantages.
-64.91%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-9.32%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency.
463.83%
EBITDA change of 463.83% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
148.36%
Margin change of 148.36% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
143.07%
Operating income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
141.66%
Margin change of 141.66% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-184.88%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-151.50%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-149.81%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
113.03%
Tax expense change of 113.03% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
-154.14%
Net income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-152.37%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-148.34%
EPS decline while Drug Manufacturers - Specialty & Generic median is -2.13%. Seth Klarman would investigate causes.
-145.86%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -0.87%. Seth Klarman would investigate causes.
23.88%
Share count change of 23.88% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
23.19%
Diluted share change of 23.19% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.